Cidara Therapeutics Current Cash

Cidara Therapeutics (CDTX) currently reports a current cash of $290M as of September 2025. That compares with $130M in the prior-year period — up 130.5% year over year. Use the charts on this page to explore Cidara Therapeutics's current cash history and peer comparisons.

Cidara Therapeutics's current cash increased from $130M to $290M — a 130.5% year-over-year increase (period ending September 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cidara Therapeutics reported $290M in current cash as of September 2025. That compares with $130M in the prior-year period — up 130.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $290M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Cidara Therapeutics, and consider following CDTX for alerts when major investors trade the stock.

Cidara Therapeutics is classified in the Healthcare sector. On current cash, it currently shows $290M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CDTX with unrelated industries.